TRPV4 Channels Mediate Bladder Cancer Cell Proliferation, Migration and Chemoresistance Article (Faculty180)

cited authors

  • Katari, Venkatesh; Dalal, Kesha; Kondapalli, Narendra; Paruchuri, Sailaja; Nadiminty, Nagalakshmi; Thodeti, Charles K

description

  • Bladder cancer (BLCA) is the second most common urologic cancer in the US and worldwide which mostly affects the aging population. Despite several ongoing clinical trials, treatment paradigms for BLCA have not changed significantly. Here, we investigated the expression of transient receptor potential vanilloid type 4 (TRPV4) in BLCA patients and its role in calcium influx, cell proliferation, and migration using normal human urothelial cells and BLCA cells. Bioinformatic analysis of the UALCAN and cBioPortal databases revealed that TRPV4 expression is significantly higher in human BLCA tissues compared to adjacent normal tissues. Further, the TRPV4 expression was markedly elevated in early-stage BLCA and upregulated in muscle-invasive bladder cancer (MIBC) tissues. TRPV4 is expressed in both normal urothelial (SV-HUC-1) and BLCA (T-24) cells and functional assays demonstrated enhanced TRPV4-mediated calcium influx in T-24 compared to SV-HUC-1 cells. T-24 cells exhibited higher spreading on extracellular matrix (ECM) gels with increasing stiffness (0.2, 8, and 50 kPa) and exhibited migratory phenotype compared to SV-HUC-1 cells. Pharmacological inhibition of TRPV4 significantly reduced proliferation and migration in T-24 cells but had minimal effects on normal cells. Finally, treatment with cisplatin significantly reduced TRPV4 protein levels and TRPV4-mediated calcium influx in chemosensitive UM-UC-3 cells, which remained unchanged in chemoresistant T-24 cells, suggesting a potential role of TRPV4 in chemoresistance. In conclusion, TRPV4 may contribute to bladder cancer progression by regulating cell proliferation and migration and may impart resistance to chemotherapy. Targeting TRPV4 could present a novel therapeutic approach for managing bladder cancer progression and overcoming chemoresistance.

authors

publication date

  • 2025

published in